Actuate Therapeutics Inc

NASDAQ:ACTU

Biotechnology

Healthcare
$2.09 +2.96%

+$0.06 today

Market cap
$50.01M
Beta
0.53
P/E (TTM)
-2.3
EPS (TTM)
-$0.92
52W Low $1.58High $9.22

Volume 0.03M

Average 0.16M

ACTU Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Actuate Therapeutics IncNASDAQ: ACTU

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash grows, but more slowly than its trailing trend

Q1 FY2026 net change in cash of $5.03M (cash outflow) rose 5.7% year over year, behind the +133.1% change in trailing-twelve-month net change in cash. Sequentially, it rose 33.5% from the prior quarter. Over 3 fiscal years it compounded at +45.7% a year.

Context

  • Net change in cash increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +5.7% toward the trailing-twelve-month pace of +133.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.03M+33.5% QoQ
Last fiscal yearDec 2025
$4.52M-20.5% YoY
LTMMar 2026
$4.24M+133.1% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.7%——
1 year-20.5%——
3-year CAGR+45.7%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
4.52M USD
Year-over-year change
-20.5%
3-year CAGR
+45.7%

Net Change in Cash vs competitors

How ACTU compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +133.1% is the 3rd highest of 9, against a peer median of -65.8%.
  • Over three fiscal years its annual growth of +45.7% compares with a peer median of -16.9%.
ACTU Competitors
Net Change in Cash for ACTU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$119.99M USD+2260.7%——
MOLNMolecular Partners AGLTM Mar 2026CHF 41.33M CHF-462.5%+5.2%—
ALECAlector, Inc.LTM Mar 2026$38.99M USD+212.8%—211.7%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$29.02M USD-44.3%—2529.6%
NKTXNkarta, Inc.LTM Mar 2026$25.24M USD-87.2%——
SPROSpero Therapeutics, Inc.LTM Mar 2026$7.24M USD+121.7%+53.7%13.2%
ACTUActuate Therapeutics IncLTM Mar 2026$4.24M USD+133.1%+45.7%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026$4.08M USD-162.5%-47.7%—
PEPGPepGen Inc.LTM Mar 2026$1.48M USD-98.4%-39.0%—
Peer median (excluding ACTU) —-65.8%-16.9%211.7%

Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(20.16M)(24.74M)(27.29M)(22.23M)
Depreciation & Amortization0000
Deferred Income Tax0000
Stock-Based Compensation654.07K423.54K2M6.05M
Change in Working Capital1.73M2.57M1.1M(3.05M)
Accounts Receivables0000
Inventory0000
Accounts Payables586.26K1.29M(1.5M)(512.54K)
Other Working Capital1.15M1.28M2.6M(2.53M)
Other Non-Cash Items(20.38K)123.46K2.35M20.25K
Operating Cash Flow(17.79M)(21.63M)(21.84M)(19.21M)
Capital Expenditures0000
Acquisitions (Net)0000
Purchases of Investments0000
Sales of Investments0000
Other Investing Activities0000
Investing Cash Flow0000
Debt Repayment005.5M0
Common Stock Issued0023.96M24.03M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities00(1.93M)(302.83K)
Financing Cash Flow19.26M4.13M27.53M23.72M
Effect of Forex Changes0000
Net Change in Cash1.46M(17.49M)5.68M4.52M
Free Cash Flow(17.79M)(21.63M)(21.84M)(19.21M)

Actuate Therapeutics Inc

NASDAQ:ACTU

Intrinsic Alpha fair value

Locked

Current Price

$2.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.